{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:30:54Z","timestamp":1787009454361,"version":"build-2736575974"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The role of tyrosine kinase inhibitors (TKIs) in early-stage and metastatic oncogene-driven non\u2013small cell lung cancer (NSCLC) is established, but it remains unknown how best to integrate TKIs with concurrent chemoradiotherapy (cCRT) in locally advanced disease. The phase 2 ASCENT trial assessed the efficacy and safety of afatinib and cCRT with or without surgery in locally advanced epidermal growth factor receptor (EGFR)-mutant NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Adults \u226518 years with histologically confirmed stage III (AJCC 7th edition) NSCLC with activating EGFR mutations were enrolled at Mass General and Dana-Farber\/Brigham Cancer Centers, Boston, Massachusetts. Patients received induction afatinib 40 mg daily for 2 months, then cisplatin 75 mg\/m2 and pemetrexed 500 mg\/m2 IV every 3 weeks during RT (definitive or neoadjuvant dosing). Patients with resectable disease underwent surgery. All patients were offered consolidation afatinib for 2 years. The primary endpoint was the objective response rate (ORR) to induction TKI. Secondary endpoints were safety, conversion to operability, progression-free survival (PFS), and overall survival (OS). Analyses were performed on the intention-to-treat population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nineteen patients (median age 56 years; 74% female) were enrolled. ORR to induction afatinib was 63%. Seventeen patients received cCRT; 2\/9 previously unresectable became resectable. Ten underwent surgery; 6 had a major or complete pathological response. Thirteen received consolidation afatinib. With a median follow-up of 5.0 years, median PFS and OS were 2.6 (95% CI, 1.4-3.1) and 5.8 years (2.9-NR), respectively. Sixteen recurred or died; 6 recurrences were isolated to CNS. The median time to progression after stopping consolidation TKI was 2.9 months (95% CI, 1.1-7.2). Four developed grade 2 pneumonitis. There were no treatment-related deaths.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We explored the efficacy of combining TKI with cCRT in oncogene-driven NSCLC. Induction TKI did not compromise subsequent receipt of multimodality therapy. PFS was promising, but the prevalence of CNS-only recurrences and rapid progression after TKI discontinuation speak to unmet needs in measuring and eradicating micrometastatic disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae107","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T08:32:08Z","timestamp":1715243528000},"page":"609-618","source":"Crossref","is-referenced-by-count":19,"title":["The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3169-8337","authenticated-orcid":false,"given":"Allison E B","family":"Chang","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, Massachusetts General Hospital , Boston, MA 02114 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"Piper-Vallillo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, Lahey Hospital and Medical Center , Burlington, MA 01805 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond H","family":"Mak","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dana Farber Cancer Institute , Boston, MA 02215 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lanuti","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Thoracic Surgery, Massachusetts General Hospital , Boston, MA 02114 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7585-8181","authenticated-orcid":false,"given":"Alona","family":"Muzikansky","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Biostatistics Center , Boston, MA 02114 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Rotow","sequence":"additional","affiliation":[{"name":"Lowe Center for Thoracic Medical Oncology, Dana Farber Cancer Institute , Boston, MA 02115 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasi A","family":"J\u00e4nne","sequence":"additional","affiliation":[{"name":"Lowe Center for Thoracic Medical Oncology, Dana Farber Cancer Institute , Boston, MA 02115 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Mino-Kenudson","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital , Boston, MA 02114 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Swanson","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Thoracic Surgery, Brigham and Women\u2019s Hospital , Boston, MA 02115 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron D","family":"Wright","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Thoracic Surgery, Massachusetts General Hospital , Boston, MA 02114 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kozono","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dana Farber Cancer Institute , Boston, MA 02215 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Marcoux","sequence":"additional","affiliation":[{"name":"Lowe Center for Thoracic Medical Oncology, Dana Farber Cancer Institute , Boston, MA 02115 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zofia","family":"Piotrowska","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, Massachusetts General Hospital , Boston, MA 02114 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lecia V","family":"Sequist","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, Massachusetts General Hospital , Boston, MA 02114 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Willers","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital , Boston, MA 02114 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,18]]},"reference":[{"issue":"24","key":"2024070911243691000_CIT0001","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"2024070911243691000_CIT0002","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC Trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"issue":"21","key":"2024070911243691000_CIT0003","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"2024070911243691000_CIT0004","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O\u2019Brien","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10","key":"2024070911243691000_CIT0005","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.annonc.2023.07.001","article-title":"Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial","volume":"34","author":"Felip","year":"2023","journal-title":"Ann Oncol"},{"issue":"18","key":"2024070911243691000_CIT0006","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"key":"2024070911243691000_CIT0007","volume-title":"LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II\u2013IIIb NSCLC","author":"Cascone","year":"2023"},{"issue":"6","key":"2024070911243691000_CIT0008","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"2024070911243691000_CIT0009","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR Mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2024070911243691000_CIT0010","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","article-title":"Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis","volume":"12","author":"Lee","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"6","key":"2024070911243691000_CIT0011","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jtho.2021.01.1628","article-title":"Durvalumab for stage III EGFR-mutated NSCLC after definitive chemoradiotherapy","volume":"16","author":"Aredo","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2024070911243691000_CIT0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2024.01.012","article-title":"Consolidation osimertinib versus durvalumab versus observation after concurrent chemoradiation in unresectable EGFR-Mutant NSCLC: a multicenter retrospective cohort study","author":"Nassar","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"9","key":"2024070911243691000_CIT0013","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"2024070911243691000_CIT0014","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2024070911243691000_CIT0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"2024070911243691000_CIT0016","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"issue":"18","key":"2024070911243691000_CIT0017","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non\u2013small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"2024070911243691000_CIT0018","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"2024070911243691000_CIT0019","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer","volume":"390","author":"Drilon","year":"2024","journal-title":"N Engl J Med"},{"issue":"14","key":"2024070911243691000_CIT0020","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"2024070911243691000_CIT0021","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.cllc.2020.11.004","article-title":"Osimertinib maintenance after definitive chemoradiation in patients with unresectable EGFR mutation positive stage III non-small-cell lung cancer: LAURA trial in progress","volume":"22","author":"Lu","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"2024070911243691000_CIT0022","volume-title":"Tagrisso Demonstrated Overwhelming Efficacy Benefit for Patients With Unresectable, Stage III EGFR-Mutated Lung Cancer in LAURA Phase III Trial","author":"Kemp","year":"2024"},{"issue":"2","key":"2024070911243691000_CIT0023","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"27","key":"2024070911243691000_CIT0024","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"2024070911243691000_CIT0025","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"2024070911243691000_CIT0026","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","volume":"17","author":"Park","year":"2016","journal-title":"Lancet Oncol"},{"key":"2024070911243691000_CIT0027","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0","author":"USDOHAH Services","year":"2009"},{"issue":"8","key":"2024070911243691000_CIT0028","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/JTO.0b013e31812f3c1a","article-title":"The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours","volume":"2","author":"Goldstraw","year":"2007","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2024070911243691000_CIT0029","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"16","key":"2024070911243691000_CIT0030","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1200\/JCO.2002.03.055","article-title":"Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019","volume":"20","author":"Albain","year":"2002","journal-title":"J Clin Oncol"},{"issue":"19","key":"2024070911243691000_CIT0031","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/jnci\/djr325","article-title":"Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410","volume":"103","author":"Curran","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"2024070911243691000_CIT0032","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1200\/JCO.2015.64.8824","article-title":"PROCLAIM: randomized phase III Trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer","volume":"34","author":"Senan","year":"2016","journal-title":"J Clin Oncol"},{"key":"2024070911243691000_CIT0033","volume-title":"LBA2 ALINA: Efficacy and Safety of Adjuvant Alectinib Versus Chemotherapy in Patients With Early-Stage ALK+ Non-Small Cell Lung Cancer (NSCLC)","author":"Solomon","year":"2023"},{"key":"2024070911243691000_CIT0034","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.8508","volume-title":"Phase II Trial of Neoadjuvant Osimertinib for Surgically Resectable EGFR-Mutated Non-Small Cell Lung Cancer","author":"Aredo","year":"2023"},{"key":"2024070911243691000_CIT0035","doi-asserted-by":"crossref","first-page":"100659","DOI":"10.1016\/j.ctarc.2022.100659","article-title":"Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer","volume":"33","author":"Aredo","year":"2022","journal-title":"Cancer Treat Res Commun"},{"issue":"1","key":"2024070911243691000_CIT0036","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ijrobp.2023.03.042","article-title":"Neoadjuvant osimertinib followed by sequential definitive radiation therapy and\/or surgery in stage III epidermal growth factor receptor-mutant non-small cell lung cancer: an open-label, single-arm, phase 2 study","volume":"117","author":"Peled","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024070911243691000_CIT0037","doi-asserted-by":"crossref","first-page":"107414","DOI":"10.1016\/j.lungcan.2023.107414","article-title":"Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: emerging evidence and future perspectives","volume":"187","author":"Kato","year":"2024","journal-title":"Lung Cancer"},{"issue":"31","key":"2024070911243691000_CIT0038","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.2217\/fon-2021-0549","article-title":"Neoadjuvant osimertinib with\/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA","volume":"17","author":"Tsuboi","year":"2021","journal-title":"Future Oncol"},{"issue":"3","key":"2024070911243691000_CIT0039","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1016\/j.cllc.2016.12.013","article-title":"Superior treatment response and in-field tumor control in epidermal growth factor receptor-mutant genotype of stage III nonsquamous non-small cell lung cancer undergoing definitive concurrent chemoradiotherapy","volume":"18","author":"Lim","year":"2017","journal-title":"Clin Lung Cancer"},{"issue":"22","key":"2024070911243691000_CIT0040","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1158\/0008-5472.CAN-19-3883","article-title":"Modeling resistance and recurrence patterns of combined targeted-chemoradiotherapy predicts benefit of shorter induction period","volume":"80","author":"McClatchy","year":"2020","journal-title":"Cancer Res"},{"issue":"3","key":"2024070911243691000_CIT0041","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jtho.2018.11.019","article-title":"Quality of life in NSCLC survivors - a multicenter cross-sectional study","volume":"14","author":"Hechtner","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"16","key":"2024070911243691000_CIT0042","doi-asserted-by":"crossref","first-page":"17239","DOI":"10.1002\/cam4.6296","article-title":"Quality-of-life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia","volume":"12","author":"Chen","year":"2023","journal-title":"Cancer Med"},{"key":"2024070911243691000_CIT0043","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.8540","volume-title":"Minimal residual disease (MRD) detection by ctDNA in relation to radiographic disease progression in patients with stage I-III non\u2013small cell lung cancer (NSCLC) treated with definitive radiation therapy","author":"Lebow","year":"2022"},{"issue":"15","key":"2024070911243691000_CIT0044","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1158\/1078-0432.CCR-21-3044","article-title":"Perioperative ctDNA-based molecular residual disease detection for non-small cell lung cancer: a prospective multicenter cohort study (LUNGCA-1)","volume":"28","author":"Xia","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"20","key":"2024070911243691000_CIT0045","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","article-title":"Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-Mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity","volume":"22","author":"Ballard","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"33","key":"2024070911243691000_CIT0046","doi-asserted-by":"crossref","first-page":"JCO2018783118","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS Response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"2024070911243691000_CIT0047","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.21037\/tlcr-22-832","article-title":"Real-world analysis of first-line afatinib in patients with EGFR-mutant non-small cell lung cancer and brain metastasis: survival and prognostic factors","volume":"12","author":"Kim","year":"2023","journal-title":"Transl Lung Cancer Res"},{"issue":"5","key":"2024070911243691000_CIT0048","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s12325-024-02799-9","article-title":"Clinical management of patients with non-small cell lung cancer, brain metastases, and actionable genomic alterations: a systematic literature review","volume":"41","author":"Khasraw","year":"2024","journal-title":"Adv Ther"},{"issue":"11","key":"2024070911243691000_CIT0049","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1093\/annonc\/mdw322","article-title":"Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials","volume":"27","author":"Yang","year":"2016","journal-title":"Ann Oncol"},{"issue":"16","key":"2024070911243691000_CIT0050","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1200\/JCO.22.02547","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"41","author":"Sequist","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"2024070911243691000_CIT0051","doi-asserted-by":"crossref","first-page":"100191","DOI":"10.1016\/j.esmoop.2021.100191","article-title":"Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902\/OLCSG0905 phase II study","volume":"6","author":"Hotta","year":"2021","journal-title":"ESMO Open"},{"issue":"29","key":"2024070911243691000_CIT0052","doi-asserted-by":"crossref","first-page":"e16427","DOI":"10.1097\/MD.0000000000016427","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors combined with thoracic radiotherapy or chemoradiotherapy for advanced or metastatic non-small cell lung cancer: a systematic review and meta-analysis of single-arm trials","volume":"98","author":"Liu","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"2024070911243691000_CIT0053","doi-asserted-by":"crossref","first-page":"981","DOI":"10.4143\/crt.2016.522","article-title":"Incorporating erlotinib or irinotecan plus cisplatin into chemoradiotherapy for stage III non-small cell lung cancer according to EGFR mutation status","volume":"49","author":"Lee","year":"2017","journal-title":"Cancer Res Treat"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/7\/609\/58481150\/oyae107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/7\/609\/58481150\/oyae107.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T07:41:49Z","timestamp":1720510909000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/7\/609\/7676393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,18]]},"references-count":53,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,5,18]]},"published-print":{"date-parts":[[2024,7,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae107","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,5,18]]}}}